[go: up one dir, main page]

WO2009022652A1 - HLA-A3スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なLck由来ペプチド - Google Patents

HLA-A3スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なLck由来ペプチド Download PDF

Info

Publication number
WO2009022652A1
WO2009022652A1 PCT/JP2008/064317 JP2008064317W WO2009022652A1 WO 2009022652 A1 WO2009022652 A1 WO 2009022652A1 JP 2008064317 W JP2008064317 W JP 2008064317W WO 2009022652 A1 WO2009022652 A1 WO 2009022652A1
Authority
WO
WIPO (PCT)
Prior art keywords
hla
lck
positive
cancer
derived peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/064317
Other languages
English (en)
French (fr)
Inventor
Kyogo Itoh
Masanori Noguchi
Mamoru Harada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kurume University
Original Assignee
Kurume University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kurume University filed Critical Kurume University
Priority to JP2009528113A priority Critical patent/JP4972691B2/ja
Publication of WO2009022652A1 publication Critical patent/WO2009022652A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　本発明は、HLA-A3スーパータイプアレル陽性癌患者の処置または予防に有用なLck由来ペプチドを提供する。具体的には、本発明は、Lck90-99、Lck449-458およびLck450-458（配列番号４、１７および１８）のペプチドを提供する。該ペプチドは、HLA-A3スーパータイプアレル分子に結合でき、かつペプチド特異的CTL誘導能を有する。本発明は、これまでに癌ワクチン候補ペプチドが多数同定されているHLA-A2またはHLA-A24分子が陰性の癌患者の治療に特に有用である。
PCT/JP2008/064317 2007-08-16 2008-08-08 HLA-A3スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なLck由来ペプチド Ceased WO2009022652A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009528113A JP4972691B2 (ja) 2007-08-16 2008-08-08 ＨＬＡ−Ａ３スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なＬｃｋ由来ペプチド

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-212179 2007-08-16
JP2007212179 2007-08-16

Publications (1)

Publication Number Publication Date
WO2009022652A1 true WO2009022652A1 (ja) 2009-02-19

Family

ID=40350705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/064317 Ceased WO2009022652A1 (ja) 2007-08-16 2008-08-08 HLA-A3スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なLck由来ペプチド

Country Status (2)

Country Link
JP (1) JP4972691B2 (ja)
WO (1) WO2009022652A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015060235A1 (ja) * 2013-10-21 2015-04-30 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド
US9102715B2 (en) 2007-09-18 2015-08-11 Green Peptide Co., Ltd. CTL inducer composition
JP2016060710A (ja) * 2014-09-17 2016-04-25 学校法人近畿大学 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤
JP2016065027A (ja) * 2014-09-26 2016-04-28 学校法人近畿大学 Ｈｌａ−ａ３スーパータイプアレル陽性の前立腺癌患者に対する癌ワクチン療法に有用なｅｚｈ２由来ペプチド
EP3360886A4 (en) * 2015-10-08 2019-06-12 Oncotherapy Science, Inc. PEPTIDE DERIVED FROM FOXM1 AND VACCINE THEREWITH
WO2020004622A1 (ja) 2018-06-29 2020-01-02 大鵬薬品工業株式会社 抗腫瘍剤及びその評価方法
WO2021132550A1 (ja) 2019-12-26 2021-07-01 大鵬薬品工業株式会社 術後補助療法剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HARASHIMA N ET AL: "Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T Lymphocytes of cancer patients with distant metastases", EUR. J. IMMUNOL, vol. 31, no. 2, 2001, pages 323 - 332, XP002212358 *
IMAI N ET AL: "Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases", INT. J. CANCER, vol. 94, no. 2, 2001, pages 237 - 242, XP002212565 *
MATSUEDA S ET AL: "Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles", CLIN. CANCER RES., vol. 11, no. 19, 2005, pages 6933 - 6943, XP003004983 *
MINAMI T ET AL: "Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles", CANCER IMMUNOL. IMMUNOTHER, vol. 56, no. 5, May 2007 (2007-05-01), pages 689 - 698, XP019489780 *
NAITO M ET AL: "Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles", BR. J. CANCER, vol. 97, no. 12, 2007, pages 1648 - 1654 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642900B2 (en) 2007-09-18 2017-05-09 Green Peptide Co., Ltd. CTL inducer composition
US9102715B2 (en) 2007-09-18 2015-08-11 Green Peptide Co., Ltd. CTL inducer composition
JP2017171678A (ja) * 2013-10-21 2017-09-28 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド
US10137183B2 (en) 2013-10-21 2018-11-27 Taiho Pharmaceutical Co., Ltd. Peptide compositions having 4 linked CTL epitopes and uses thereof
CN105658673A (zh) * 2013-10-21 2016-06-08 大鹏药品工业株式会社 新型的具有4个连接的ctl表位的肽
JPWO2015060235A1 (ja) * 2013-10-21 2017-03-09 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド
CN105658673B (zh) * 2013-10-21 2019-07-26 大鹏药品工业株式会社 新型的具有4个连接的ctl表位的肽
AU2014337643B2 (en) * 2013-10-21 2017-07-13 Taiho Pharmaceutical Co., Ltd. Novel four-CTL epitope-joined peptide
WO2015060235A1 (ja) * 2013-10-21 2015-04-30 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド
JP2016060710A (ja) * 2014-09-17 2016-04-25 学校法人近畿大学 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤
JP2016065027A (ja) * 2014-09-26 2016-04-28 学校法人近畿大学 Ｈｌａ−ａ３スーパータイプアレル陽性の前立腺癌患者に対する癌ワクチン療法に有用なｅｚｈ２由来ペプチド
EP3360886A4 (en) * 2015-10-08 2019-06-12 Oncotherapy Science, Inc. PEPTIDE DERIVED FROM FOXM1 AND VACCINE THEREWITH
AU2016335731B2 (en) * 2015-10-08 2021-05-06 Oncotherapy Science, Inc. FOXM1-derived peptide, and vaccine including same
US11242365B2 (en) 2015-10-08 2022-02-08 Oncotherapy Science, Inc. FOXM1-derived peptide, and vaccine including same
EP4219525A3 (en) * 2015-10-08 2023-09-27 OncoTherapy Science, Inc. Foxm1-derived peptide, and vaccine including same
WO2020004622A1 (ja) 2018-06-29 2020-01-02 大鵬薬品工業株式会社 抗腫瘍剤及びその評価方法
US12251447B2 (en) 2018-06-29 2025-03-18 Taiho Pharmaceutical Co., Ltd. Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer
WO2021132550A1 (ja) 2019-12-26 2021-07-01 大鵬薬品工業株式会社 術後補助療法剤

Also Published As

Publication number Publication date
JP4972691B2 (ja) 2012-07-11
JPWO2009022652A1 (ja) 2010-11-18

Similar Documents

Publication Publication Date Title
WO2009022652A1 (ja) HLA-A3スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なLck由来ペプチド
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
WO2006081826A3 (en) Survivin peptide vaccine
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ601677A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
TW200744642A (en) Novel peptides for use in the treatment of obesity
PH12013500714A1 (en) Anticancer fusion protein
PH12014501083A1 (en) Anticancer fusion protein
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
WO2009038026A1 (ja) Ｃｔｌ誘導剤組成物
WO2009072610A1 (ja) 癌ワクチン組成物
WO2008087186A3 (en) Peptides for use in the treatment of obesity
WO2008110579A3 (en) Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and their use in cancer treatment.
WO2011073215A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2008087188A3 (en) Peptides for use in the treatment of obesity
MX355054B (es) Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo.
MX2011013972A (es) Peptido novedoso y su uso.
NO20084053L (no) Inhibering av tumorvekst
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
WO2009072555A1 (ja) 癌ワクチン

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827222

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009528113

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08827222

Country of ref document: EP

Kind code of ref document: A1